

=> d his

(FILE 'HOME' ENTERED AT 09:25:26 ON 24 FEB 2005)

L1 FILE 'HCAPLUS' ENTERED AT 09:25:31 ON 24 FEB 2005
6 (US20040171818 OR US20050037982)/PN

FILE 'REGISTRY' ENTERED AT 09:26:18 ON 24 FEB 2005

L2 FILE 'HCAPLUS' ENTERED AT 09:26:20 ON 24 FEB 2005
TRA L1 1- RN : 724 TERMS

L3 FILE 'REGISTRY' ENTERED AT 09:26:21 ON 24 FEB 2005
724 SEA 02

L4 FILE 'WPIX' ENTERED AT 09:26:26 ON 24 FEB 2005
1 (US20040171818 OR US20050037982)/PN

=> b hcap

FILE 'HCAPLUS' ENTERED AT 09:26:51 ON 24 FEB 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 24 Feb 2005 VOL 142 ISS 9
FILE LAST UPDATED: 23 Feb 2005 (20050223/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all 11 tot

L1 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN
AN 2005:140788 HCAPLUS
ED Entered STN: 18 Feb 2005
TI 6-11 bicyclic ketolide derivatives
IN Or, Yat Sun; Wang, Guoqiang; Phan, Ly Tam; Niu, Deqiang; Vo, Nha Huu; Qiu, Yao-ling; Wang, Yanchun; Busuyek, Marina; Hou, Ying; Peng, Yulin; Kim, Heejin; Liu, Tongzhu; Farmer, Jay Judson; Xu, Guoyou
PA USA
SO U.S. Pat. Appl. Publ., 210 pp., Cont.-in-part of U.S. Ser. No. 144,558, abandoned.
CODEN: USXXCO
DT Patent
LA English
IC ICM C07H017-08
ICS A61K031-7048
NCL 514028000; 536007100
CC 33 (Carbohydrates)
FAN.CNT 10

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

PI US 2005037982 A1 20050217 US 2003-429485 20030505 <--
 WO 2003097659 A1 20031127 WO 2003-US14669 20030509
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 EP 1506214 A1 20050216 EP 2003-733983 20030509
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 US 2004157787 A1 20040812 US 2003-717290 20031119
 US 2004171818 A1 20040902 US 2004-758409 20040114 <--
 US 2005009761 A1 20050113 US 2004-763377 20040123
 PRAI US 2002-144558 B2 20020513
 US 2002-144396 B2 20020513
 US 2002-205018 - A2 20020725
 US 2002-205357 A2 20020725
 US 2003-429485 A 20030505
 WO 2003-US14669 W 20030509
 US 2003-436622 A2 20030513
 US 2003-464188 A2 20030618

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 20050037982	ICM	C07H017-08
	ICS	A61K031-7048
	NCL	514028000; 536007100
US 2004157787	ECLA	C07H017/08F
US 2004171818	ECLA	C07H017/08F

US 20050037982 ICM C07H017-08
 ICS A61K031-7048
 NCL 514028000; 536007100
 US 2004157787 ECLA C07H017/08F
 US 2004171818 ECLA C07H017/08F <--

AB The present invention discloses compounds of formula I, or
 pharmaceutically acceptable salts, esters, or prodrugs thereof: 1 which
 exhibit antibacterial properties. The present invention further relates
 to pharmaceutical compositions comprising the aforementioned compounds for
 administration to a subject in need of antibiotic treatment. The
 invention also relates to methods of treating a bacterial infection in a
 subject by administering a pharmaceutical composition comprising the
 compounds of the present invention. The invention further includes
 process by which to make the compounds of the present invention.

L1 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2005:34589 HCAPLUS

DN 142:114362

ED Entered STN: 14 Jan 2005

TI Preparation of glycoside bridged macrocyclic compounds as antibacterial
 agents

IN Or, Yat Sun

PA USA

SO U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S. Ser. No. 464,188.
 CODEN: USXXCO

DT Patent

LA English

IC ICM C07H017-08

ICS A61K031-7048

NCL 514028000; 536007100

CC 33-7 (Carbohydrates)

Section cross-reference(s): 1, 10, 63

FAN.CNT 10

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

PI	US 2005009761	A1	20050113	US 2004-763377	20040123
	US 2004023895	A1	20040205	US 2002-205018	20020725
	US 6841664	B2	20050111		
	US 6753318	B1	20040622	US 2002-205357	20020725
	US 2005037982	A1	20050217	US 2003-429485	20030505 <--
	US 2004053861	A1	20040318	US 2003-436622	20030513
	US 6764998	B1	20040720	US 2003-464188	20030618
PRAI	US 2002-144396	B2	20020513		
	US 2002-144558	B2	20020513		
	US 2002-205018	A2	20020725		
	US 2002-205357	A2	20020725		
	US 2003-429485	A2	20030505		
	US 2003-436622	A2	20030513		
	US 2003-464188	A2	20030618		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2005009761	ICM	C07H017-08
	ICS	A61K031-7048
	NCL	514028000; 536007100
US 2004023895	ECLA	C07H017/08F
US 2004053861	ECLA	C07H017/08F

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention provides a method for preparing bridged macrocyclic glycosides, e.g. I, wherein R is H, acyl, silane, hydroxy protecting group; L and R3 are independently H, aliphatic, alicyclic, aromatic, heteroarom., heterocyclic; one of U or V is H and the other is independently selected from R4, . OR4, OC(O)R4, oxy-amide, S(O)nR4, sugar residue; R4 is H, deuterium, alkyl, alicyclic, aromatic, heterocyclic; U and V, taken together with the carbon atom to which they are attached, are C:O, or UV and R1R2, taken together with the carbon atoms to which they are attached, are -C(R4)CH-; X and Y together with the carbon atom to which they are attached are CO, imine, oxime; X1 is H or halogen; n is 0-2, comprising the step of reacting a macrocyclic compound characterized by having at least two nucleophilic moieties with a bi-functional bridging reagent optionally in the presence of a catalyst, thereby producing a bridged macrocyclic product. Thus, macrolide II was prepared as potential antibacterial agent. This invention also encompasses pharmaceutical compns. containing, and methods of treating bacterial infections through administering, pharmaceutically acceptable prodrugs of compds. produced by the process of the present invention (no data).

ST aminodeoxy glycoside macrocyclic prepn antibacterial

IT Glycosides

RL: SPN (Synthetic preparation); PREP (Preparation)
(amino; preparation of glycoside bridged macrocyclic compds. as antibacterial agents)

IT Macrolides

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);
BIOL (Biological study); PREP (Preparation)
(preparation of glycoside bridged macrocyclic compds. as antibacterial agents)

IT 110-64-5, 2-Butene-1,4-diol 3513-81-3 13127-18-9 76801-85-9
652150-15-7

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of glycoside bridged macrocyclic compds. as antibacterial agents)

IT 116700-73-3P 134297-05-5P 314050-27-6P 620161-75-3P 625390-08-1P
625390-10-5P 652150-16-8P 652157-58-9P 823802-96-6P 823802-97-7P

823802-99-9P 823803-00-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of glycoside bridged macrocyclic compds. as antibacterial agents)

IT 620161-76-4P 823802-98-8P 823803-01-6P 823803-03-8P 823803-04-9P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of glycoside bridged macrocyclic compds. as antibacterial agents)

L1 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:722951 HCAPLUS

DN 141:225773

ED Entered STN: 03 Sep 2004

TI Processes for the preparation of 6-11-bicyclic erythromycin derivatives via palladium-catalyzed condensation reaction

IN Xu, Guoyou; Tang, Datong; Gai, Yonghua; Kim, Heejin; Wang, Guoqiang; Phan, Ly Tam; Or, Yat Sun; Wang, Zhe

PA USA

SO U.S. Pat. Appl. Publ., 25 pp., Cont.-in-part of U.S. Ser. No. 436,622.

CODEN: USXXCO

DT Patent

LA English

IC ICM C07H017-08

NCL 536007400

CC 33-7 (Carbohydrates)

Section cross-reference(s): 1. 63

FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004171818	A1	20040902	US 2004-758409	20040114 <--
	US 2005037982	A1	20050217	US 2003-429485	20030505 <--
	US 2004053861	A1	20040318	US 2003-436622	20030513
PRAI	US 2002-144396	B2	20020513		
	US 2002-144558	B2	20020513		
	US 2003-429485	A2	20030505		
	US 2003-436622	A2	20030513		

CLASS

PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES

US 2004171818	ICM	C07H017-08	
	NCL	536007400	
US 2004171818	ECLA	C07H017/08F	<--
US 2004053861	ECLA	C07H017/08F	

OS CASREACT 141:225773; MARPAT 141:225773

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to processes and intermediates for the preparation of 6-11 bicyclic erythromycin derivs. I, wherein R-R2 are independently selected from hydrogen, acyl, silane, aliphatic group, alicyclic group, aromatic group, heteroarom. group, saturated or unsatd. heterocyclic; Q is independently selected from R2, alkoxy, ester, heterocycle; Z is independently selected from R2, alkoxy, ester, amide, oxy-sulfonyl, were prepared I was prepared via palladium-catalyzed condensation of macrolide II with ester III. In particular, the present invention relates to processes and intermediates for the preparation of a macrolide IV.

ST prodrug erythromycin amino glycoside prepn palladium catalyzed condensation macrolide; bicyclic erythromycin amino glycoside prepn

palladium catalyzed condensation ester

IT Macrolides
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP
 (Preparation)
 (glycosides; processes for preparation of bicyclic erythromycin derivs. via
 palladium catalyzed condensation reaction)

IT Glycosides
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP
 (Preparation)
 (lactones, macrolides; processes for preparation of bicyclic erythromycin
 derivs. via palladium catalyzed condensation reaction)

IT Condensation reaction
 Condensation reaction catalysts
 (processes for preparation of bicyclic erythromycin derivs. via palladium
 catalyzed condensation reaction)

IT 7440-05-3, Palladium, uses 51364-51-3, Pd2(dba)3
 RL: CAT (Catalyst use); USES (Uses)
 (processes for preparation of bicyclic erythromycin derivs. via palladium
 catalyzed condensation reaction)

IT 314050-27-6P 321533-62-4P 620161-75-3P 620161-78-6P 628703-61-7P
 748796-37-4P 748796-38-5P 748796-39-6P 748796-40-9P
 RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic
 preparation); PREP (Preparation); RACT (Reactant or reagent)
 (processes for preparation of bicyclic erythromycin derivs. via palladium
 catalyzed condensation reaction)

IT 625390-37-6P 748796-41-0P 748797-36-6P
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP
 (Preparation)
 (processes for preparation of bicyclic erythromycin derivs. via palladium
 catalyzed condensation reaction)

IT 288-13-1, Pyrazole 524-38-9, n-Hydroxyphthalimide 3513-81-3,
 2-Methylene-1,3-propanediol 13127-18-9, Erythromycin a oxime
 24424-99-5, Di-tert-butyl dicarbonate 73781-91-6, Methyl
 6-chloronicotinate
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (processes for preparation of bicyclic erythromycin derivs. via palladium
 catalyzed condensation reaction)


IT 7688-25-7, 1,4-Bis(diphenylphosphino)butane
 RL: RGT (Reagent); RACT (Reactant or reagent)
 (processes for preparation of bicyclic erythromycin derivs. via palladium
 catalyzed condensation reaction)

L1 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN
 AN 2004:652626 HCAPLUS
 DN 141:190995
 ED Entered STN: 13 Aug 2004
 TI Preparation of 6-11-bicyclic erythromycin ketolide derivatives as
 antibacterial agents
 IN Or, Yat Sun; Guoqiang, Wang; Phan, Ly Tam; Niu, Deqiang; Vo, Nha Huu; Qiu,
 Yao-Ling; Wang, Yanchun; Busuyek, Marina; Hou, Ying; Peng, Yulin; Kim,
 Heejin; Liu, Tongzhu; Farmer, Jay Judson; Xu, Guoyav
 PA USA
 SO U.S. Pat. Appl. Publ., 156 pp., Cont.-in-part of U.S. Ser. No. 429,485.
 CODEN: USXXCO
 DT Patent
 LA English
 IC ICM A61K031-7048
 ICS C07H017-08
 NCL 514028000; 536007400
 CC 33-7 (Carbohydrates)
 Section cross-reference(s): 1, 10, 63
 FAN.CNT 10

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

CLASS

US 2004157787 ICM A61K031-7048
ICS C07H017-08
NCL 514028000: 536007400
US 2004157787 ECLA C07H017/08F
OS MARPAT 141:190995
GI



I

ST human bicyclic erythromycin ketolide macrolide glycoside prepn
antibacterial]

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino; preparation of bicyclic erythromycin ketolide derivs. as antibacterial agents)

(bacterial; preparation of bicyclic erythromycin ketolide derivs. as antibacterial agents)

(macrolide; preparation of bicyclic erythromycin ketolide derivs. as antibacterial agents)

Search done by Noble Jarrell

Human

(preparation of bicyclic erythromycin ketolide derivs. as antibacterial agents)

IT 14221-01-3, Tetrakis(triphenylphosphine)palladium 31210-36-3
51364-51-3, Pd2(dba)3

RL: CAT (Catalyst use); USES (Uses)

(preparation of bicyclic erythromycin ketolide derivs. as antibacterial agents)

IT	628698-55-5P	628698-56-6P	628698-59-9P	628698-60-2P	628698-61-3P
	628698-62-4P	628698-64-6P	628698-66-8P	628698-67-9P	628698-68-0P
	628698-69-1P	628698-70-4P	628698-71-5P	628698-72-6P	628698-74-8P
	628698-75-9P	628698-81-7P	628698-82-8P	628698-83-9P	628698-84-0P
	628698-85-1P	628698-86-2P	628698-87-3P	628698-88-4P	628698-89-5P
	628698-90-8P	628698-91-9P	628698-92-0P	628698-93-1P	628698-94-2P
	628698-95-3P	628698-96-4P	628698-97-5P	628698-98-6P	628698-99-7P
	628699-00-3P	628699-01-4P	628699-02-5P	628699-03-6P	628699-04-7P
	628699-05-8P	628699-06-9P	628699-07-0P	628699-08-1P	628699-09-2P
	628699-10-5P	628699-11-6P	628699-12-7P	628699-13-8P	628699-15-0P
	628699-16-1P	628699-17-2P	628699-18-3P	628699-19-4P	628699-20-7P
	628699-21-8P	628699-22-9P	628699-23-0P	628699-24-1P	628699-25-2P
	628699-26-3P	628699-27-4P	628699-28-5P	628699-29-6P	628699-30-9P
	628699-31-0P	628699-32-1P	628699-33-2P	628699-34-3P	628699-35-4P
	628699-36-5P	628699-37-6P	628699-38-7P	628699-39-8P	628699-40-1P
	628699-41-2P	628699-42-3P	628699-43-4P	628699-44-5P	628699-45-6P
	628699-46-7P	628699-47-8P	628699-48-9P	628699-49-0P	628699-50-3P
	628699-51-4P	628699-52-5P	628699-53-6P	628699-54-7P	628699-55-8P
	628699-56-9P	628699-57-0P	628699-58-1P	628699-59-2P	628699-60-5P
	628699-61-6P	628699-62-7P	628699-63-8P	628699-64-9P	628699-65-0P
	628699-66-1P	628699-67-2P	628699-68-3P	628699-69-4P	628699-70-7P
	628699-71-8P	628699-72-9P	628699-73-0P	628699-74-1P	628699-75-2P
	628699-76-3P	628699-77-4P	628699-78-5P	628699-79-6P	628699-80-9P
	628699-81-0P	628699-82-1P	628699-83-2P	628699-84-3P	628699-85-4P
	628699-86-5P	628699-87-6P	628699-88-7P	628699-89-8P	628699-90-1P
	628699-91-2P	628699-92-3P	628699-93-4P	628699-94-5P	628699-95-6P
	628699-96-7P	628699-97-8P	628699-98-9P	628699-99-0P	628700-00-5P
	628700-01-6P	628700-02-7P	628700-03-8P	628700-04-9P	628700-05-0P
	628700-06-1P	628700-07-2P	628700-08-3P	628700-09-4P	628700-10-7P
	628700-11-8P	628700-12-9P	628700-13-0P	628700-14-1P	628700-15-2P
	628700-18-5P	628700-19-6P	628700-20-9P	628700-21-0P	628700-22-1P
	628700-23-2P	628700-24-3P	628700-25-4P	628700-26-5P	628700-27-6P
	628700-28-7P	628700-29-8P	628700-30-1P	628700-31-2P	628700-32-3P
	628700-33-4P	628700-34-5P	628700-35-6P	628700-36-7P	628700-37-8P
	628700-38-9P	628700-39-0P	628700-40-3P	628700-42-5P	628700-44-7P
	628700-45-8P	628700-47-0P	628700-49-2P	628700-52-7P	628700-54-9P
	628700-56-1P	628700-58-3P	628700-60-7P	628700-62-9P	628700-64-1P
	628700-66-3P	628700-68-5P	628700-69-6P	628700-71-0P	628700-73-2P
	628700-75-4P	628700-77-6P	628700-79-8P	628700-81-2P	628700-83-4P
	628700-85-6P	628700-87-8P	628700-89-0P	628700-91-4P	628700-93-6P
	628700-95-8P	628700-96-9P	628700-98-1P	628701-00-8P	628701-02-0P
	628701-03-1P	628701-04-2P	628701-05-3P	628701-07-5P	628701-09-7P
	628701-10-0P	628701-12-2P	628701-13-3P	628701-15-5P	628701-17-7P
	628701-18-8P	628701-19-9P	628701-21-3P	628701-23-5P	628701-25-7P
	628701-28-0P	628701-31-5P	628701-34-8P	628701-36-0P	628701-38-2P
	628701-40-6P	628701-43-9P	628701-45-1P	628701-47-3P	628701-49-5P
	628701-51-9P	628701-53-1P	628701-55-3P	628701-57-5P	

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN

(Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);

PREP (Preparation); USES (Uses)

(preparation of bicyclic erythromycin ketolide derivs. as antibacterial agents)

IT	628701-59-7P	628701-61-1P	628701-63-3P	628701-64-4P	628701-65-5P
	628701-66-6P	628701-68-8P	628701-69-9P	628701-70-2P	628701-71-3P
	628701-73-5P	628701-74-6P	628701-75-7P	628701-76-8P	628701-77-9P
	628701-78-0P	628701-79-1P	628701-80-4P	628701-81-5P	628701-82-6P

628701-83-7P	628701-84-8P	628701-85-9P	628701-86-0P	628701-88-2P
628701-90-6P	628701-91-7P	628701-93-9P	628701-94-0P	628701-95-1P
628701-96-2P	628701-97-3P	628701-98-4P	628701-99-5P	628702-01-2P
628702-03-4P	628702-05-6P	628702-06-7P	628702-07-8P	628702-08-9P
628702-09-0P	628702-10-3P	628702-11-4P	628702-12-5P	628702-14-7P
628702-16-9P	628702-18-1P	628702-20-5P	628702-21-6P	628702-22-7P
628702-24-9P	628702-25-0P	628702-27-2P	628702-28-3P	628702-30-7P
628702-32-9P	628702-35-2P	628702-36-3P	628702-37-4P	628702-38-5P
628702-39-6P	628702-40-9P	628702-41-0P	628702-42-1P	628702-43-2P
628702-44-3P	628702-45-4P	628702-46-5P	628702-47-6P	628702-48-7P
628702-49-8P	628702-50-1P	628702-51-2P	628702-52-3P	628702-53-4P
628702-54-5P	628702-55-6P	628702-56-7P	628702-57-8P	628702-58-9P
628702-59-0P	628702-60-3P	628702-61-4P	628702-62-5P	628702-63-6P
628702-64-7P	628702-65-8P	628702-66-9P	628702-67-0P	628702-68-1P
628702-69-2P	628702-70-5P	628702-71-6P	628702-72-7P	628702-73-8P
628702-74-9P	628702-75-0P	628702-76-1P	628702-77-2P	628702-78-3P
628702-79-4P	628702-80-7P	628702-81-8P	628702-82-9P	628702-83-0P
628702-84-1P	628702-85-2P	628702-89-6P	628702-90-9P	628702-92-1P
628702-93-2P	628702-94-3P	628702-95-4P	628702-97-6P	628702-98-7P
628702-99-8P	628703-00-4P	628703-01-5P	628703-06-0P	628703-09-3P
628703-10-6P	628703-11-7P	628703-12-8P	628703-13-9P	628703-14-0P
628703-15-1P	628703-19-5P	628703-26-4P	628708-46-3P	628708-48-5P
628708-49-6P	628708-50-9P	628708-51-0P	628708-52-1P	

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of bicyclic erythromycin ketolide derivs. as antibacterial agents)

IT 116700-73-3P	123784-07-6P	620161-75-3P	625389-96-0P	625389-97-1P
625389-98-2P	625390-00-3P	625390-04-7P	625390-05-8P	625390-08-1P
625390-10-5P	625390-12-7P	625390-14-9P	625390-16-1P	625390-18-3P
625390-20-7P	625390-28-5P	625390-30-9P	625390-31-0P	625390-32-1P
625390-35-4P	628698-52-2P	628698-53-3P	628698-54-4P	628698-73-7P
628702-86-3P	628702-87-4P	628702-88-5P	628702-91-0P	628702-96-5P
628703-02-6P	628703-03-7P	628703-04-8P	628703-05-9P	628703-16-2P
628703-17-3P	628703-18-4P	628703-20-8P	628703-21-9P	628703-22-0P
628703-23-1P	628703-24-2P	628703-25-3P	628703-27-5P	736992-12-4P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of bicyclic erythromycin ketolide derivs. as antibacterial agents)

IT 62-53-3, Aniline, reactions	64-04-0, Phenethylamine	80-17-1	92-66-0
100-39-0	100-46-9, Benzylamine, reactions	101-55-3	103-64-0,
.beta.-Bromostyrene	105-36-2	504-29-0, 2-Pyridinamine	524-38-9,
N-Hydroxyphthalimide	590-17-0	591-50-4, Iodobenzene	613-94-5
622-30-0, Benzylhydroxylamine	622-33-3	932-87-6	1034-49-7
1449-46-3	1589-82-8, Benzylmagnesium bromide	1730-25-2, Allylmagnesium	
bromide	1782-39-4	1944-96-3	2038-57-5, Benzenepropanamine
2113-57-7	2567-29-5	3277-89-2, Phenethylmagnesium bromide	3319-99-1
3360-54-1	3513-81-3	4616-54-0	4732-11-0
4930-98-7	5332-24-1	7688-25-7	13214-66-9, Benzenebutanamine
14704-31-5	15256-11-8	18462-35-6	26146-77-0
26776-70-5,			
1,3-Dihydroxyacetone dimer	27570-08-7	30777-95-8	30777-96-9
33675-41-1	36881-42-2	37756-48-2	37832-20-5
39854-54-1	52552-21-3	54624-57-6	55418-29-6
55418-32-1	58841-74-0		
60691-90-9	64908-64-1	66305-82-6	72915-12-9
74771-11-2	78254-23-6	79349-78-3	83670-46-6
87413-09-0, Dess-Martin reagent			
92856-14-9	94115-39-6	111321-02-9	115665-71-9
133609-18-4			
133745-75-2, N-Fluorobenzenesulfonimide		144429-18-5	149649-90-1
150191-56-3	154357-82-1	160725-45-1	198694-68-7
205111-38-2	205111-39-3	205111-41-7	205114-21-2
207746-06-3	218431-37-9		
218431-38-0	291530-89-7	313343-88-3	500891-77-0
545423-63-0	545423-64-1	545445-38-3	628698-63-5
628698-65-7	628698-76-0		
628698-77-1	628698-78-2	628698-79-3	628698-80-6
628700-16-3			

628700-17-4 628703-07-1 628703-08-2 628703-28-6 628703-29-7
 628703-30-0 628703-31-1 628703-32-2 628703-33-3 628703-34-4
 628703-35-5 628703-36-6 628703-38-8 628703-39-9 628703-40-2
 628703-41-3 628703-42-4 628703-43-5 628703-46-8 628703-48-0
 628703-50-4 628703-51-5 628703-52-6 628703-53-7 628703-54-8
 628703-55-9 628703-56-0 628703-57-1 628703-58-2 628703-59-3
 628703-60-6 628703-61-7 628703-62-8 628703-63-9 628703-64-0
 628703-65-1 628703-66-2 628703-67-3 628703-68-4 628703-69-5
 628703-70-8 628703-71-9 628703-72-0 628703-73-1 628703-74-2
 628703-75-3 628703-76-4 628703-77-5 628703-78-6 628703-79-7
 628703-80-0 628703-81-1 628703-82-2 628703-83-3 628703-84-4
 628703-85-5 628703-86-6 628703-87-7 628703-88-8 628703-89-9
 628703-90-2 628703-91-3 628703-92-4 628703-93-5 628703-94-6
 628703-95-7 628703-96-8 628703-97-9 628703-98-0 628703-99-1
 628704-00-7 628704-01-8 628704-02-9 628704-03-0 628704-04-1
 628704-05-2 628704-06-3 628704-07-4 628704-08-5 628704-09-6
 628704-10-9 628704-11-0 628704-12-1 628704-13-2 628704-14-3
 628704-15-4 628704-16-5 628704-17-6 628704-18-7 628704-19-8
 628704-20-1 628704-21-2 628704-22-3 628704-23-4 628704-24-5
 628704-25-6 628704-26-7 628704-27-8 628704-28-9 628704-29-0
 628704-30-3 628704-31-4 628704-32-5 628704-33-6 628704-34-7
 628704-35-8 628704-36-9 628704-37-0 628704-38-1 628704-39-2
 628704-40-5 628704-41-6 628704-42-7 628704-43-8 628704-44-9
 628704-45-0 628704-46-1 628704-47-2 628704-48-3 628704-49-4
 628704-50-7 628704-51-8 628704-52-9 628704-53-0 628704-54-1
 628704-55-2 628704-56-3 628704-57-4 628704-58-5 628704-59-6
 628704-60-9 628704-61-0 628704-62-1 628704-63-2 628704-64-3
 628704-65-4 628704-66-5 628708-47-4

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of bicyclic erythromycin ketolide derivs. as antibacterial agents)

IT 87742-13-0

RL: RGT (Reagent); RACT (Reactant or reagent)

(preparation of bicyclic erythromycin ketolide derivs. as antibacterial agents)

L1 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:220028 HCAPLUS

DN 140:236004

ED Entered STN: 19 Mar 2004

TI Preparation of 6,11-bicyclic erythromycin macrolides as antibacterial agents

IN Or, Yat Sun; Wang, Guoqiang; Phan, Ly Tam; Niu, Deqiang; Qiu, Yao-Ling; Vo, Nha Huu; Farmer, Jay Judson; Hou, Ying

PA USA

SO U.S. Pat. Appl. Publ., 43 pp., Cont.-in-part of U.S. Ser. No. 144,396, abandoned.

CODEN: USXXCO

DT Patent

LA English

IC ICM A61K031-7048

ICS A61K031-7052; C07H017-08

NCL 514028000; 536007100; 536017400

CC 33-7 (Carbohydrates)

Section cross-reference(s): 1, 10, 63


FAN.CNT 10

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004053861	A1	20040318	US 2003-436622	20030513
	US 2004171818	A1	20040902	US 2004-758409	20040114 <--
	US 2005009761	A1	20050113	US 2004-763377	20040123
PRAI	US 2002-144396	B2	20020513		
	US 2002-144558	B2	20020513		
	US 2002-205018	A2	20020725		

US 2002-205357	A2	20020725
US 2003-429485	A2	20030505
US 2003-436622	A2	20030513
US 2003-464188	A2	20030618

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
US 2004053861	ICM	A61K031-7048
	ICS	A61K031-7052; C07H017-08
	NCL	514028000; 536007100; 536017400
US 2004053861	ECLA	C07H017/08F
US 2004171818	ECLA	C07H017/08F
OS	CASREACT 140:236004; MARPAT 140:236004	
GI		



AB 6.11-Bicyclic erythromycin macrolides I, wherein A is OH, OR1, R1 is hydroxy protecting group, aryl, heteroaryl, O-aryl, O-heteroaryl, H, halogen, alkyl, alkenyl, alkynyl, sulfonyl, amide, sulfonamide, amine; B is H, deuterium, halogen, OH, aryl, heteroaryl, OR1; A and B together are O, acetal, thioacetal, acyl, alkene, oxime; X and Y are independently H, deuterium, OR1, amine; X and Y together are CO, imine; L is Me, Et, CH(OH)Me, alkyl, alkenyl, alkynyl; W is amine; Z is H, OH, OR1, alkoxy, ester, O-amide, sulfonyl, heterocycle, or pharmaceutically acceptable salts, esters, or prodrugs thereof which exhibit antibacterial properties. The present invention further relates to pharmaceutical compns. comprising the aforementioned compds. for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compds. of the present invention. The invention further includes process by which to make the compds. of the present invention. Title compds. were tested for in vitro antibacterial activity by a micro-dilution method and demonstrated an MIC in the range from about 64 .mu.g/mL to about 0.03 .mu.g/mL. According to the methods of treatment of the present invention, bacterial infections are treated or prevented in a patient such as a human or other animals by administering to the patient a therapeutically effective amount of a compound of the invention, in such amts. and for such time as is necessary to achieve the desired result (no data). Thus, I (A and B together with the carbon atom to which they are attached = C:CH2, X and Y together with the carbon atom to which they are attached = C:NAC, L = Et, W is NMe2, Z = R = H) was prepared and tested as antibacterial agent.

ST bicyclic erythromycin macrolide prepn antibacterial human prodrug

IT Antibiotics

(aminoglycoside; preparation of bicyclic erythromycin macrolides as antibacterial agents)

IT Infection

(bacterial; preparation of bicyclic erythromycin macrolides as antibacterial agents)

IT Antibiotics

(macrolide; preparation of bicyclic erythromycin macrolides as antibacterial agents)

IT Antibacterial agents
Antibiotics
Human
(preparation of bicyclic erythromycin macrolides as antibacterial agents)

IT Drug delivery systems
(prodrugs; preparation of bicyclic erythromycin macrolides as antibacterial agents)

IT 625390-06-9P 625390-26-3P 625390-39-8P 625390-42-3P 625390-44-5P
625390-48-9P 625390-49-0P 625390-51-4P 625390-52-5P 625390-53-6P
625390-54-7P 625390-55-8P 625390-56-9P 625390-57-0P 625390-58-1P
625390-59-2P 625390-60-5P 625390-61-6P 625390-62-7P 625390-63-8P
625390-64-9P 625390-65-0P
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of bicyclic erythromycin macrolides as antibacterial agents)

IT 625389-96-0P 625389-97-1P 625389-98-2P 625389-99-3P 625390-00-3P
625390-02-5P 625390-03-6P 625390-04-7P 625390-05-8P 625390-08-1P
625390-12-7P 625390-14-9P 625390-16-1P 625390-18-3P 625390-20-7P
625390-22-9P 625390-24-1P 625390-28-5P 625390-30-9P 625390-31-0P
625390-32-1P 625390-33-2P 625390-34-3P 625390-35-4P 625390-36-5P
625390-37-6P 625390-38-7P 625390-40-1P 625390-41-2P 625390-43-4P
625390-45-6P 625390-46-7P 625390-47-8P 625390-50-3P 628703-03-7P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of bicyclic erythromycin macrolides as antibacterial agents)

IT 103-64-0, .beta.-Bromostyrene 501-81-5, 3-Pyridylacetic acid
1449-46-3, Benzyl triphenylphosphonium bromide 5332-24-1,
3-Bromoquinoline 7688-25-7, 1,4-Bis(diphenylphosphino)butane
13115-43-0, 2-Pyridylacetic acid 26776-70-5, 1,3-Dihydroxyacetone dimer
111321-02-9 315193-22-7 620161-75-3 625390-10-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of bicyclic erythromycin macrolides as antibacterial agents)

L1 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:931379 HCAPLUS

DN 140:16927

ED Entered STN: 28 Nov 2003

TI Preparation of 6-11 bicyclic erythromycin ketolide derivatives as antibacterial agents

IN Or, Yat Sun; Wang, Guoqiang; Phan, Ly Tam; Niu, Deqiang; Vo, Nha Huu; Qiu, Yao-ling; Wang, Yanchun; Busuyek, Marina; Hou, Ying; Peng, Yulin; Kim, Heejin; Liu, Tongzhu; Farmer, Jay Judson; Xu, Guoyou

PA Enanta Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 249 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C07H017-08

ICS A61K031-7048; A61P031-04

CC 33-7 (Carbohydrates)

Section cross-reference(s): 1, 10, 63

FAN.CNT 10

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003097659	A1	20031127	WO 2003-US14669	20030509
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005037982 A1 20050217 US 2003-429485 20030505 <--
 EP 1506214 A1 20050216 EP 2003-733983 20030509

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK


PRAI US 2002-144558 A 20020513
 US 2003-429485 A 20030505
 WO 2003-US14669 W 20030509

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2003097659	ICM	C07H017-08
	ICS	A61K031-7048; A61P031-04

OS MARPAT 140:16927

GI



I

AB 6-11 Bicyclic erythromycin ketolide derivs. I, wherein A is OH, ORp, where Rp is a hydroxy protecting group, R1, where R1 is aryl, heteroaryl, OR1, R2, where R2 is H, halogen, alkyl, alkenyl, alkynyl, OR2, amine, amide, sulfonyl, sulfonamide; B is H, deuterium, halogen, OH, R1, R2, ORp; A and B together with the carbon atom to which they are attached form CO, ketal, thioketal, alkylidene, oxime; one of X and Y is H and the other is H, deuterium, OH, ORp, amine; X and Y are together CO, imine; L is Me, Et, CH(OH)Me, alkyl, alkenyl, alkynyl; W is amine; Z is H, Me, halogen; R2' is H, Rp, were prepared as antibacterial agents. Thus, bicyclic erythromycin ketolide I, wherein A and B taken together with the carbon atom to which they are attached are C=CH2, X and Y taken together with the carbon atom to which they are attached are C=N-Ac, L = CHCH3, Z = H, and R2' = Ac, was prepared and tested in vitro as antibacterial agent. The compds. of the invention demonstrated in vitro antibacterial activity of MIC in the range from about 64 .mu.g/mL to about 0.03 .mu.g/mL. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compds. of the present invention. The present invention further relates to pharmaceutical compns. comprising the aforementioned compds. for administration to a subject in need of antibiotic treatment.

ST human bicyclic erythromycin ketolide macrolide glycoside prepn
 antibacterial

IT Glycosides

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(amino; preparation of bicyclic erythromycin ketolide derivs. as
 antibacterial agents)

IT Antibiotics

(aminoglycoside; preparation of bicyclic erythromycin ketolide derivs. as

antibacterial agents)

IT Infection
(bacterial; preparation of bicyclic erythromycin ketolide derivs. as
antibacterial agents)

IT Antibiotics
(macrolide; preparation of bicyclic erythromycin ketolide derivs. as
antibacterial agents)

IT Antibacterial agents
Antibiotics
Human
(preparation of bicyclic erythromycin ketolide derivs. as antibacterial
agents)

IT 14221-01-3, Tetrakis(triphenylphosphine)palladium 31210-36-3
51364-51-3, Pd2(dba)3
RL: CAT (Catalyst use); USES (Uses)
(preparation of bicyclic erythromycin ketolide derivs. as antibacterial
agents)

IT 628698-55-5P 628698-56-6P 628698-59-9P 628698-60-2P 628698-61-3P
628698-62-4P 628698-64-6P 628698-66-8P 628698-67-9P 628698-68-0P
628698-69-1P 628698-70-4P 628698-71-5P 628698-72-6P 628698-74-8P
628698-75-9P 628698-81-7P 628698-82-8P 628698-83-9P 628698-84-0P
628698-85-1P 628698-86-2P 628698-87-3P 628698-88-4P 628698-89-5P
628698-90-8P 628698-91-9P 628698-92-0P 628698-93-1P 628698-94-2P
628698-95-3P 628698-96-4P 628698-97-5P 628698-98-6P 628698-99-7P
628699-00-3P 628699-01-4P 628699-02-5P 628699-03-6P 628699-04-7P
628699-05-8P 628699-06-9P 628699-07-0P 628699-08-1P 628699-09-2P
628699-10-5P 628699-11-6P 628699-12-7P 628699-13-8P 628699-15-0P
628699-16-1P 628699-17-2P 628699-18-3P 628699-19-4P 628699-20-7P
628699-21-8P 628699-22-9P 628699-23-0P 628699-24-1P 628699-25-2P
628699-26-3P 628699-27-4P 628699-28-5P 628699-29-6P 628699-30-9P
628699-31-0P 628699-32-1P 628699-33-2P 628699-34-3P 628699-35-4P
628699-36-5P 628699-37-6P 628699-38-7P 628699-39-8P 628699-40-1P
628699-41-2P 628699-42-3P 628699-43-4P 628699-44-5P 628699-45-6P
628699-46-7P 628699-47-8P 628699-48-9P 628699-49-0P 628699-50-3P
628699-51-4P 628699-52-5P 628699-53-6P 628699-54-7P 628699-55-8P
628699-56-9P 628699-57-0P 628699-58-1P 628699-59-2P 628699-60-5P
628699-61-6P 628699-62-7P 628699-63-8P 628699-64-9P 628699-65-0P
628699-66-1P 628699-67-2P 628699-68-3P 628699-69-4P 628699-70-7P
628699-71-8P 628699-72-9P 628699-73-0P 628699-74-1P 628699-75-2P
628699-76-3P 628699-77-4P 628699-78-5P 628699-79-6P 628699-80-9P
628699-81-0P 628699-82-1P 628699-83-2P 628699-84-3P 628699-85-4P
628699-86-5P 628699-87-6P 628699-88-7P 628699-89-8P 628699-90-1P
628699-91-2P 628699-92-3P 628699-93-4P 628699-94-5P 628699-95-6P
628699-96-7P 628699-97-8P 628699-98-9P 628699-99-0P 628700-00-5P
628700-01-6P 628700-02-7P 628700-03-8P 628700-04-9P 628700-05-0P
628700-06-1P 628700-07-2P 628700-08-3P 628700-09-4P 628700-10-7P
628700-11-8P 628700-12-9P 628700-13-0P 628700-14-1P 628700-15-2P
628700-18-5P 628700-19-6P 628700-20-9P 628700-21-0P 628700-22-1P
628700-23-2P 628700-24-3P 628700-25-4P 628700-26-5P 628700-27-6P
628700-28-7P 628700-29-8P 628700-30-1P 628700-31-2P 628700-32-3P
628700-33-4P 628700-34-5P 628700-35-6P 628700-36-7P 628700-37-8P
628700-38-9P 628700-39-0P 628700-40-3P 628700-42-5P 628700-44-7P
628700-45-8P 628700-47-0P 628700-49-2P 628700-52-7P 628700-54-9P
628700-56-1P 628700-58-3P 628700-60-7P 628700-62-9P 628700-64-1P
628700-66-3P 628700-68-5P 628700-69-6P 628700-71-0P 628700-73-2P
628700-75-4P 628700-77-6P 628700-79-8P 628700-81-2P 628700-83-4P
628700-85-6P 628700-87-8P 628700-89-0P 628700-91-4P 628700-93-6P
628700-95-8P 628700-96-9P 628700-98-1P 628701-00-8P 628701-02-0P
628701-03-1P 628701-04-2P 628701-05-3P 628701-07-5P 628701-09-7P
628701-10-0P 628701-12-2P 628701-13-3P 628701-15-5P 628701-17-7P
628701-18-8P 628701-19-9P 628701-21-3P 628701-23-5P 628701-25-7P
628701-28-0P 628701-31-5P 628701-34-8P 628701-36-0P 628701-38-2P
628701-40-6P 628701-43-9P 628701-45-1P 628701-47-3P 628701-49-5P
628701-51-9P 628701-53-1P 628701-55-3P 628701-57-5P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of bicyclic erythromycin ketolide derivs. as antibacterial agents)

IT	628701-59-7P	628701-61-1P	628701-63-3P	628701-64-4P	628701-65-5P
	628701-66-6P	628701-68-8P	628701-69-9P	628701-70-2P	628701-71-3P
	628701-73-5P	628701-74-6P	628701-75-7P	628701-76-8P	628701-77-9P
	628701-78-0P	628701-79-1P	628701-80-4P	628701-81-5P	628701-82-6P
	628701-83-7P	628701-84-8P	628701-85-9P	628701-86-0P	628701-88-2P
	628701-90-6P	628701-91-7P	628701-93-9P	628701-94-0P	628701-95-1P
	628701-96-2P	628701-97-3P	628701-98-4P	628701-99-5P	628702-01-2P
	628702-03-4P	628702-05-6P	628702-06-7P	628702-07-8P	628702-08-9P
	628702-09-0P	628702-10-3P	628702-11-4P	628702-12-5P	628702-14-7P
	628702-16-9P	628702-18-1P	628702-20-5P	628702-21-6P	628702-22-7P
	628702-24-9P	628702-25-0P	628702-27-2P	628702-28-3P	628702-30-7P
	628702-32-9P	628702-35-2P	628702-36-3P	628702-37-4P	628702-38-5P
	628702-39-6P	628702-40-9P	628702-41-0P	628702-42-1P	628702-43-2P
	628702-44-3P	628702-45-4P	628702-46-5P	628702-47-6P	628702-48-7P
	628702-49-8P	628702-50-1P	628702-51-2P	628702-52-3P	628702-53-4P
	628702-54-5P	628702-55-6P	628702-56-7P	628702-57-8P	628702-58-9P
	628702-59-0P	628702-60-3P	628702-61-4P	628702-62-5P	628702-63-6P
	628702-64-7P	628702-65-8P	628702-66-9P	628702-67-0P	628702-68-1P
	628702-69-2P	628702-70-5P	628702-71-6P	628702-72-7P	628702-73-8P
	628702-74-9P	628702-75-0P	628702-76-1P	628702-77-2P	628702-78-3P
	628702-79-4P	628702-80-7P	628702-81-8P	628702-82-9P	628702-83-0P
	628702-84-1P	628702-85-2P	628702-89-6P	628702-90-9P	628702-92-1P
	628702-93-2P	628702-94-3P	628702-95-4P	628702-97-6P	628702-98-7P
	628702-99-8P	628703-00-4P	628703-01-5P	628703-06-0P	628703-09-3P
	628703-10-6P	628703-11-7P	628703-12-8P	628703-13-9P	628703-14-0P
	628703-15-1P	628703-19-5P	628703-26-4P	628708-46-3P	628708-48-5P
	628708-49-6P	628708-50-9P	628708-51-0P	628708-52-1P	

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of bicyclic erythromycin ketolide derivs. as antibacterial agents)

IT	116700-73-3P	123784-07-6P	620161-75-3P	625389-96-0P	625389-97-1P
	625389-98-2P	625390-00-3P	625390-04-7P	625390-05-8P	625390-08-1P
	625390-10-5P	625390-12-7P	625390-14-9P	625390-16-1P	625390-18-3P
	625390-20-7P	625390-28-5P	625390-30-9P	625390-31-0P	625390-32-1P
	625390-35-4P	628698-52-2P	628698-53-3P	628698-54-4P	628698-73-7P
	628702-86-3P	628702-87-4P	628702-88-5P	628702-91-0P	628702-96-5P
	628703-02-6P	628703-03-7P	628703-04-8P	628703-05-9P	628703-16-2P
	628703-17-3P	628703-18-4P	628703-20-8P	628703-21-9P	628703-22-0P
	628703-23-1P	628703-24-2P	628703-25-3P	628703-27-5P	

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of bicyclic erythromycin ketolide derivs. as antibacterial agents)

IT	62-53-3, Aniline, reactions	64-04-0, Phenethylamine	80-17-1	92-66-0
	100-39-0	100-46-9, Benzylamine, reactions	101-55-3	103-64-0,
	.beta.-Bromostyrene	105-36-2	504-29-0, 2-Pyridinamine	524-38-9,
	N-Hydroxyphthalimide	590-17-0	591-50-4, Iodobenzene	613-94-5
	622-30-0, Benzylhydroxylamine	622-33-3	932-87-6	1034-49-7
	1449-46-3	1589-82-8, Benzylmagnesium bromide	1730-25-2, Allylmagnesium	
	bromide	1782-39-4	1944-96-3	2038-57-5, Benzenepropanamine
	2113-57-7	2567-29-5	3277-89-2, Phenethylmagnesium bromide	3319-99-1
	3360-54-1	3513-81-3	4616-54-0	4732-11-0
	4930-98-7	5332-24-1	7688-25-7	13214-66-9, Benzenebutanamine
	14704-31-5	15256-11-8	18462-35-6	26146-77-0
	26776-70-5,			
	1,3-Dihydroxyacetone dimer	27570-08-7	30777-95-8	30777-96-9
	33675-41-1	36881-42-2	37756-48-2	37832-20-5
	39854-54-1			
	52552-21-3	54624-57-6	55418-29-6	55418-32-1
				58841-74-0

60691-90-9 64908-64-1 66305-82-6 72915-12-9 74771-11-2
 78254-23-6 79349-78-3 83670-46-6 87413-09-0, Dess-Martin reagent
 92856-14-9 94115-39-6 111321-02-9 115665-71-9 133609-18-4
 133745-75-2, N-Fluorobenzenesulfonimide 144429-18-5 149649-90-1
 150191-56-3 154357-82-1 160725-45-1 198694-68-7 205111-38-2
 205111-39-3 205111-41-7 205114-21-2 207746-06-3 218431-37-9
 218431-38-0 291530-89-7 313343-88-3 500891-77-0 545423-63-0
 545423-64-1 545445-38-3 628698-63-5 628698-65-7 628698-76-0
 628698-77-1 628698-78-2 628698-79-3 628698-80-6 628700-16-3
 628700-17-4 628703-03-7 628703-07-1 628703-08-2 628703-28-6
 628703-29-7 628703-30-0 628703-31-1 628703-32-2 628703-33-3
 628703-34-4 628703-35-5 628703-36-6 628703-38-8 628703-39-9
 628703-40-2 628703-41-3 628703-42-4 628703-43-5 628703-46-8
 628703-48-0 628703-50-4 628703-51-5 628703-52-6 628703-53-7
 628703-54-8 628703-55-9 628703-56-0 628703-57-1 628703-58-2
 628703-59-3 628703-60-6 628703-61-7 628703-62-8 628703-63-9
 628703-64-0 628703-65-1 628703-66-2 628703-67-3 628703-68-4
 628703-69-5 628703-70-8 628703-71-9 628703-72-0 628703-73-1
 628703-74-2 628703-75-3 628703-76-4 628703-77-5 628703-78-6
 628703-79-7 628703-80-0 628703-81-1 628703-82-2 628703-83-3
 628703-84-4 628703-85-5 628703-86-6 628703-87-7 628703-88-8
 628703-89-9 628703-90-2 628703-91-3 628703-92-4 628703-93-5
 628703-94-6 628703-95-7 628703-96-8 628703-97-9 628703-98-0
 628703-99-1 628704-00-7 628704-01-8 628704-02-9 628704-03-0
 628704-04-1 628704-05-2 628704-06-3 628704-07-4 628704-08-5
 628704-09-6 628704-10-9 628704-11-0 628704-12-1 628704-13-2
 628704-14-3 628704-15-4 628704-16-5 628704-17-6 628704-18-7
 628704-19-8 628704-20-1 628704-21-2 628704-22-3 628704-23-4
 628704-24-5 628704-25-6 628704-26-7 628704-27-8 628704-28-9
 628704-29-0 628704-30-3 628704-31-4 628704-32-5 628704-33-6
 628704-34-7 628704-35-8 628704-36-9 628704-37-0 628704-38-1
 628704-39-2 628704-40-5 628704-41-6 628704-42-7 628704-43-8
 628704-44-9 628704-45-0 628704-46-1 628704-47-2 628704-48-3
 628704-49-4 628704-50-7 628704-51-8 628704-52-9 628704-53-0
 628704-54-1 628704-55-2 628704-56-3 628704-57-4 628704-58-5
 628704-59-6 628704-60-9 628704-61-0 628704-62-1 628704-63-2
 628704-64-3 628704-65-4 628704-66-5 628708-47-4

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of bicyclic erythromycin ketolide derivs. as antibacterial agents)

IT 87742-13-0

RL: RGT (Reagent); RACT (Reactant or reagent)

(preparation of bicyclic erythromycin ketolide derivs. as antibacterial agents)

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Chu, D; US 5866549 A 1999 HCAPLUS

=> b wpix

FILE WPXY ENTERED AT 09:27:09 ON 24 FEB 2005
 COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE LAST UPDATED: 18 FEB 2005 <20050218/UP>
 MOST RECENT DERWENT UPDATE: 200512 <200512/DW>
 DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
 PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
<http://thomsonderwent.com/coverage/latestupdates/> <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER GUIDES, PLEASE VISIT:
<http://thomsonderwent.com/support/userguides/> <<<

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX FIRST VIEW - FILE WPIFV.
 FOR FURTHER DETAILS: <http://www.thomsonderwent.com/dwpifv> <<<

>>> NEW DISPLAY FORMAT HITSTR ADDED ALLOWING DISPLAY OF HIT STRUCTURES WITHIN THE BIBLIOGRAPHIC DOCUMENT <<<

>>> SMILES and ISOSMILES strings are no longer available as Derwent Chemistry Resource display fields <<<

>>> THE CPI AND EPI MANUAL CODES HAVE BEEN REVISED FROM UPDATE 200501. PLEASE CHECK:
<http://thomsonderwent.com/support/dwpioref/reftools/classification/code-revision/> FOR DETAILS. <<<

=> d all 14 tot

L4 ANSWER 1 OF 1 WPIX COPYRIGHT 2005 THE THOMSON CORP on STN
 AN 2004-651704 [63] WPIX
 CR 2004-042432 [04]; 2004-061977 [06]; 2004-214344 [20]; 2004-226303 [21];
 2004-293950 [27]; 2004-542128 [52]; 2004-603360 [58]; 2005-090414 [10]
 DNC C2004-233225
 TI Preparation of 6-11 bicyclic erythromycin derivatives, useful as an intermediate in the preparation of bridged erythromycin derivatives, comprises reaction of bicyclic erythromycin derivatives with ester derivatives.
 DC B02
 IN GAI, Y; KIM, H; OR, Y S; PHAN, L T; TANG, D; WANG, G; WANG, Z; XU, G
 PA (GAIY-I) GAI Y; (KIMH-I) KIM H; (ORYS-I) OR Y S; (PHAN-I) PHAN L T;
 (TANG-I) TANG D; (WANG-I) WANG G; (WANG-I) WANG Z; (XUGG-I) XU G
 CYC 1
 PI US 2004171818 A1 20040902 (200463)* 25 C07H017-08 <--
 ADT US 2004171818 A1 CIP of US 2002-144396 20020513, CIP of US 2002-144558 20020513, CIP of US 2003-429485 20030505, CIP of US 2003-436622 20030513, US 2004-758409 20040114
 PRAI US 2004-758409 20040114; US 2002-144396 20020513;
 US 2002-144558 20020513; US 2003-429485 20030505;
 US 2003-436622 20030513
 IC ICM C07H017-08
 AB US2004171818 A UPAB: 20050211
 NOVELTY - Preparation of 6-11 bicyclic erythromycin derivatives (III) comprises reaction of bicyclic erythromycin derivatives (I) with ester derivatives (II).
 DETAILED DESCRIPTION - Preparation of 6-11 bicyclic erythromycin derivatives of formula (III) comprises reaction of bicyclic erythromycin derivatives of formula (I) with ester derivatives of formula (II).
 R1 = aliphatic, alicyclic (optionally substituted saturated), (hetero)aromatic (optionally substituted), heterocyclic (optionally saturated), H, acyl or silane; either
 R3, R4 = aliphatic, alicyclic (optionally substituted saturated), (hetero)aromatic (optionally substituted), heterocyclic (optionally saturated), H or acyl; or
 NR3R4 = heteroaromatic ring or optionally substituted heterocyclic;
 Q = R1, OR1, OC(O)R1 or pyran derivative of formula (a);
 Z = R1, OR1, OC(O)R1, OC(O)NR3R4 or OS(O)nR1; either
 J, G = H, R1, OR1 or NR3R4; or
 CUG = CO, CNR1, CNOR1, CNO(CH2)mR1, CNNHR1, CNNHCOR1, CNNHCONR3R4.

CNNHS(O)nR1 or CN-NCHR1:

R11. Rp = R1:

m = any integer; and

n = 0-2.

An INDEPENDENT CLAIM is also included for the preparation of pyridine derivative of formula (XI).

USE - (I) are useful as a intermediate in the preparation of bridged erythromycin derivatives.

ADVANTAGE - (III) increases oral availability, solubility to allow administration by injection and alter metabolism and rate of excretion.

Dwg.0/0

FS CPI

FA AB; GI: DCN

MC CPI: B02-E; B07-D04B; B07-D08

=> b home

FILE 'HOME' ENTERED AT 09:27:15 ON 24 FEB 2005

=> log h

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	42.86

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-4.38

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 09:27:18 ON 24 FEB 2005